iDNA Genomics Public (CYS:IDNA) Ending Cash Position: €0.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYS:IDNA iDNA Genomics Public Ltd CYS:IDNA
23 GF Score
Price €10.00
! 2 Warning Signs
View Full Analysis

What is iDNA Genomics Public Ending Cash Position?

iDNA Genomics Public CYS:IDNA 23 Ending Cash Position is €0.01 Mil as of Dec. 2025. GuruFocus rates CYS:IDNA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

iDNA Genomics Public's Ending Cash Position for the quarter that ended in Dec. 2025 was €0.01 Mil.

iDNA Genomics Public's quarterly Ending Cash Position declined from Dec. 2024 (€0.41 Mil) to Jun. 2025 (€0.17 Mil) and declined from Jun. 2025 (€0.17 Mil) to Dec. 2025 (€0.01 Mil).

iDNA Genomics Public's annual Ending Cash Position increased from Dec. 2023 (€0.10 Mil) to Dec. 2024 (€0.41 Mil) but then declined from Dec. 2024 (€0.41 Mil) to Dec. 2025 (€0.01 Mil).

iDNA Genomics Public Ending Cash Position Related Terms

iDNA Genomics Public Ending Cash Position Historical Data

* Premium members only.

The historical data trend for iDNA Genomics Public's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public Ending Cash Position Chart

iDNA Genomics Public Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
0.13 0.12 0.10 0.41 0.01

iDNA Genomics Public Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial 0.10 0.10 0.41 0.17 0.01
CYS:IDNA
23GF Score
iDNA Genomics Public Ltd CYS:IDNA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iDNA Genomics Public Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

iDNA Genomics Public's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.356196+-0.344334
=0.01

iDNA Genomics Public's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.104026+-0.092164
=0.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.01 Mil mean?
iDNA Genomics Public (CYS:IDNA) has a Ending Cash Position of €0.01 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on iDNA Genomics Public and its competitors.
Is iDNA Genomics Public's Ending Cash Position too high?
iDNA Genomics Public's current Ending Cash Position is €0.01 Mil. Overall, iDNA Genomics Public has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does iDNA Genomics Public's Ending Cash Position compare to ?
iDNA Genomics Public's Ending Cash Position of €0.01 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on iDNA Genomics Public and its competitors. iDNA Genomics Public's current Ending Cash Position is €0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iDNA Genomics Public stock overvalued right now?
iDNA Genomics Public (CYS:IDNA) has a current Ending Cash Position of €0.01 Mil. The current Ending Cash Position is €0.01 Mil. iDNA Genomics Public's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For iDNA Genomics Public (CYS:IDNA), the current Ending Cash Position is €0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iDNA Genomics Public Business Description

Comparable Companies
Address 7 Hatzidaki Street, Trypiotis, Nicosia, CYP, 1066
iDNA Genomics Public Ltd is a Cyprus-based biotechnology company specializing in genomics and personalized healthcare. It develops and provides genetic testing services through two main channels: Medical Genomics, which distributes tests via healthcare professionals such as physicians and clinics, and Direct-to-Consumer Genomics, which sells testing kits directly to individuals. Its products analyze genetic markers to generate personalized health, wellness, and predisposition reports for customers. The company serves individual consumers and medical professionals, primarily in Cyprus and other European markets. Revenue is generated through the sale of genetic testing kits and related analysis services, as well as through partnerships with healthcare providers.
23GF Score

Get the complete analysis for CYS:IDNA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.00
Price